{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:38:46Z","timestamp":1790307526199,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL134952"],"award-info":[{"award-number":["R01HL134952"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55643-7","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:02:41Z","timestamp":1737021761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-8989","authenticated-orcid":false,"given":"Tim","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo B. A.","family":"Laranjeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Letson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7849-0844","authenticated-orcid":false,"given":"LaYow","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared S.","family":"Fowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A. C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8112-2346","authenticated-orcid":false,"given":"Minyoung","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailen","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana San","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Jayanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-1238","authenticated-orcid":false,"given":"Stacey L.","family":"Rentschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-2975","authenticated-orcid":false,"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-8814","authenticated-orcid":false,"given":"Grant A.","family":"Challen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"55643_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: A contemporary review. JAMA Oncol. 1, 97\u2013105 (2015).","journal-title":"JAMA Oncol."},{"key":"55643_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research, N. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"55643_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-304","volume":"12","author":"A Murati","year":"2012","unstructured":"Murati, A. et al. Myeloid malignancies: mutations, models and management. BMC Cancer 12, 304 (2012).","journal-title":"BMC Cancer"},{"key":"55643_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"55643_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"55643_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi, A. M. et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27, 1861\u20131869 (2013).","journal-title":"Leukemia"},{"key":"55643_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar, A. J., Rampal, R. K. & Levine, R. Leukemia secondary to myeloproliferative neoplasms. Blood 136, 61\u201370 (2020).","journal-title":"Blood"},{"key":"55643_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477\u2013482 (2020).","journal-title":"Nature"},{"key":"55643_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","volume":"73","author":"A Rodriguez-Meira","year":"2019","unstructured":"Rodriguez-Meira, A. et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol. Cell 73, 1292\u20131305 (2019).","journal-title":"Mol. Cell"},{"key":"55643_CR10","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch, H. C. & Bjorn, M. E. MPNs as inflammatory diseases: The evidence, consequences, and perspectives. Mediators Inflamm. 2015, 102476 (2015).","journal-title":"Mediators Inflamm."},{"key":"55643_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher, D. A. C., Fowles, J. S., Zhou, A. & Oh, S. T. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front. Immunol. 12, 683401 (2021).","journal-title":"Front. Immunol."},{"key":"55643_CR12","doi-asserted-by":"publisher","unstructured":"Trowbridge, J. J., Starczynowski, D. T. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20201544 (2021).","DOI":"10.1084\/jem.20201544"},{"key":"55643_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","volume":"21","author":"T Muto","year":"2020","unstructured":"Muto, T. et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat. Immunol. 21, 535\u2013545 (2020).","journal-title":"Nat. Immunol."},{"key":"55643_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe, M. et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33, 29\u201343 (2018).","journal-title":"Cancer Cell"},{"key":"55643_CR15","doi-asserted-by":"crossref","unstructured":"Laranjeira, A. B. A. et al. In vivo ablation of NFkappaB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143, 2414\u20132424. (2024).","DOI":"10.1182\/blood.2023022804"},{"key":"55643_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/bloodadvances.2020002804","volume":"6","author":"T Kong","year":"2022","unstructured":"Kong, T. et al. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFkappaB pathway inhibition. Blood Adv. 6, 611\u2013623 (2022).","journal-title":"Blood Adv."},{"key":"55643_CR17","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/leu.2016.377","volume":"31","author":"DAC Fisher","year":"2017","unstructured":"Fisher, D. A. C. et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31, 1962\u20131974 (2017).","journal-title":"Leukemia"},{"key":"55643_CR18","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher, D. A. C. et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia 33, 1978\u20131995 (2019).","journal-title":"Leukemia"},{"key":"55643_CR19","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1128\/MCB.23.14.4796-4804.2003","volume":"23","author":"PP Roux","year":"2003","unstructured":"Roux, P. P., Richards, S. A. & Blenis, J. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol. Cell Biol. 23, 4796\u20134804 (2003).","journal-title":"Mol. Cell Biol."},{"key":"55643_CR20","doi-asserted-by":"publisher","first-page":"29325","DOI":"10.1074\/jbc.M311144200","volume":"279","author":"Y Hu","year":"2004","unstructured":"Hu, Y. et al. 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1). J. Biol. Chem. 279, 29325\u201329335 (2004).","journal-title":"J. Biol. Chem."},{"key":"55643_CR21","doi-asserted-by":"publisher","first-page":"C1336","DOI":"10.1152\/ajpcell.00552.2005","volume":"291","author":"S Xu","year":"2006","unstructured":"Xu, S., Bayat, H., Hou, X. & Jiang, B. Ribosomal S6 kinase-1 modulates interleukin-1beta-induced persistent activation of NF-kappaB through phosphorylation of IkappaBbeta. Am. J. Physiol. Cell Physiol. 291, C1336\u2013C1345 (2006).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"55643_CR22","first-page":"108","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong, T. et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat. Cancer 4, 108\u2013127 (2023).","journal-title":"Nat. Cancer"},{"key":"55643_CR23","doi-asserted-by":"publisher","unstructured":"Watanabe, D. et al. FLT3-ITD activates RSK1 to enhance proliferation and survival of AML cells by activating mTORC1 and eIF4B cooperatively with PIM or PI3K and by inhibiting bad and BIM. Cancers 11, https:\/\/doi.org\/10.3390\/cancers11121827 (2019).","DOI":"10.3390\/cancers11121827"},{"key":"55643_CR24","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.18632\/oncotarget.27630","volume":"11","author":"HD Chae","year":"2020","unstructured":"Chae, H. D. et al. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget 11, 2387\u20132403 (2020).","journal-title":"Oncotarget"},{"key":"55643_CR25","doi-asserted-by":"publisher","unstructured":"Dunn, S. E. et al. Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC). Cancer Res. 80, https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-P3-10-10 (2020).","DOI":"10.1158\/1538-7445.SABCS19-P3-10-10"},{"key":"55643_CR26","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1538-7445.AM2021-1038","volume":"81","author":"A Jayanthan","year":"2021","unstructured":"Jayanthan, A. et al. Abstract 1038: PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models. Cancer Res. 81, 1038\u20131038 (2021).","journal-title":"Cancer Res."},{"key":"55643_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28737-3","volume":"13","author":"A Erdem","year":"2022","unstructured":"Erdem, A. et al. The glycolytic gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia. Nat. Commun. 13, 1105 (2022).","journal-title":"Nat. Commun."},{"key":"55643_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"55643_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","volume":"588","author":"AK Jayavelu","year":"2020","unstructured":"Jayavelu, A. K. et al. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588, 157\u2013163 (2020).","journal-title":"Nature"},{"key":"55643_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41375-021-01393-0","volume":"36","author":"F Perner","year":"2022","unstructured":"Perner, F. et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 36, 426\u2013437 (2022).","journal-title":"Leukemia"},{"key":"55643_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2202","volume":"10","author":"AL Stratford","year":"2008","unstructured":"Stratford, A. L. et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 10, R99 (2008).","journal-title":"Breast Cancer Res."},{"key":"55643_CR32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"55643_CR33","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-018-0349-9","volume":"33","author":"JS Fowles","year":"2019","unstructured":"Fowles, J. S., How, J., Allen, M. J. & Oh, S. T. Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. Leukemia 33, 1522\u20131526 (2019).","journal-title":"Leukemia"},{"key":"55643_CR34","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/bjh.18044","volume":"197","author":"A Zhou","year":"2022","unstructured":"Zhou, A. et al. Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. Br. J. Haematol. 197, e49\u2013e52 (2022).","journal-title":"Br. J. Haematol."},{"key":"55643_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"55643_CR36","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/bloodadvances.2019000585","volume":"3","author":"A Franzini","year":"2019","unstructured":"Franzini, A. et al. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 3, 2949\u20132961 (2019).","journal-title":"Blood Adv."},{"key":"55643_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2643-3230.BCD-21-0217","volume":"3","author":"MC Ferrall-Fairbanks","year":"2022","unstructured":"Ferrall-Fairbanks, M. C. et al. Progenitor hierarchy of chronic myelomonocytic Leukemia identifies inflammatory monocytic-biased trajectory linked to worse outcomes. Blood Cancer Discov. 3, 536\u2013553 (2022).","journal-title":"Blood Cancer Discov."},{"key":"55643_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/blood.V128.22.109.109","volume":"128","author":"S Niyongere","year":"2016","unstructured":"Niyongere, S. et al. Comprehensive inflammatory cytokine profiling pdentifies IL-8\/CXCL8 As elevated, associated with proliferative features, and independently prognostic in chronic myelomonocytic Leukemia (CMML). Blood 128, 109 (2016).","journal-title":"Blood"},{"key":"55643_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584\u2013596 (2010).","journal-title":"Cancer Cell"},{"key":"55643_CR40","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).","journal-title":"PLoS Med."},{"key":"55643_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2020009676","volume":"138","author":"M Feng","year":"2021","unstructured":"Feng, M. et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood 138, 71\u201385 (2021).","journal-title":"Blood"},{"key":"55643_CR42","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher, D. A. C. et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia 33, 1978\u20131995 (2019).","journal-title":"Leukemia"},{"key":"55643_CR43","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"55643_CR44","doi-asserted-by":"crossref","unstructured":"Kong, T. et al. RSK1 dependency in FLT3-ITD acute myeloid leukemia. Blood Cancer J. 14, 207 (2024).","DOI":"10.1038\/s41408-024-01187-4"},{"key":"55643_CR45","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/2159-8290.CD-20-1652","volume":"11","author":"H Celik","year":"2021","unstructured":"Celik, H. et al. A humanized animal model predicts clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms. Cancer Discov. 11, 3126\u20133141 (2021).","journal-title":"Cancer Discov."},{"key":"55643_CR46","doi-asserted-by":"crossref","unstructured":"Wang, J. S. et al. High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor. SABCS https:\/\/aacrjournals.org\/cancerres\/article\/83\/5_Supplement\/P4-01-16\/718165\/Abstract-P4-01-16-High-levels-of-RSK2-in-breast (2022).","DOI":"10.1158\/1538-7445.SABCS22-P4-01-16"},{"key":"55643_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin, M., Clement, F., Fattaccioli, A., Raes, M. & Michiels, C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15, 577 (2015).","journal-title":"BMC Cancer"},{"key":"55643_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"55643_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"55643_CR50","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"55643_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"55643_CR52","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55643_CR53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"55643_CR54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979\u2013982 (2017).","journal-title":"Nat. Methods"},{"key":"55643_CR55","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1214\/11-AOAS466","volume":"5","author":"Q Li","year":"2011","unstructured":"Li, Q., Brown, J. B., Huang, H. & Bickel, P. J. Measuring reproducibility of high-throughput experiments. Ann. Appl. Stat. 5, 1752\u20131779, 1728 (2011).","journal-title":"Ann. Appl. Stat."},{"key":"55643_CR56","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Ahmad, K. & Henikoff, S. CUT&Tag Data Processing and Analysis Tutorial v1 (2020).","DOI":"10.17504\/protocols.io.bjk2kkye"},{"key":"55643_CR57","doi-asserted-by":"publisher","first-page":"W158","DOI":"10.1093\/nar\/gkz348","volume":"47","author":"D Li","year":"2019","unstructured":"Li, D., Hsu, S., Purushotham, D., Sears, R. L. & Wang, T. WashU epigenome browser update 2019. Nucleic Acids Res. 47, W158\u2013W165 (2019).","journal-title":"Nucleic Acids Res."},{"key":"55643_CR58","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2022-164925","volume":"140","author":"T Kong","year":"2022","unstructured":"Kong, T. et al. Comprehensive profiling of clinical JAK2 inhibitors in myeloproliferative neoplasms. Blood 140, 3951\u20133952 (2022).","journal-title":"Blood"},{"key":"55643_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"55643_CR60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid Leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"55643_CR61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid Leukemia. Cancer Cell 40, 850\u2013864.e859 (2022).","journal-title":"Cancer Cell"},{"key":"55643_CR62","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"55643_CR63","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood.2022016033","volume":"140","author":"MH Kramer","year":"2022","unstructured":"Kramer, M. H. et al. Proteomic and phosphoproteomic landscapes of acute myeloid Leukemia. Blood 140, 1533\u20131548 (2022).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55643-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55643-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55643-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:02:49Z","timestamp":1737021769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55643-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55643"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55643-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T.O. has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene\/Bristol Myers Squibb, Disc Medicine, Protagonist, Blueprint Medicines, Cogent, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. A.J., G.L., and S.E.D. are employees of Phoenix Molecular Designs. S.E.D. holds patents on utilizing RSK inhibitors for the treatment of cancer. G.A.C. has received funding for consulting and\/or sponsored research from Incyte, Ajax Therapeutics, and Renegade Therapeutics. All other authors disclose no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"492"}}